Opdivo passes Phase III gastric cancer test

Bristol-Myers Squibb Co. (NYSE:BMY) and partner Ono Pharmaceutical Co. Ltd. (Tokyo:4528) said Opdivo nivolumab met the primary endpoint of the Phase III ONO-4538-12 study as a second-line therapy for gastric cancer. The companies said Opdivo significantly improved overall survival vs. placebo in the study, which evaluated Opdivo in patients with unresectable advanced or recurrent gastric cancer refractory to or intolerant of standard therapy.

The companies said Opdivo is the first immuno-oncology candidate to show a survival benefit in the indication...